TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07764146: An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

Sponsor: Voyager Therapeutics · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,442,880

Rescue Site Savings

+$5,567,024

Unlock Full NCT07764146 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07764146 Rescue Dossier →